Clinical Trial Update: Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 safety and pharmacokinetic study of MM-302 in patients with advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MM-302 (liposomal doxorubicin (HER2-targeted))

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Breast Cancer | Phase 1 | Status: UNKNOWN